Revolution Medicines, Inc. (RVMD): M&A transaction — Revolution Medicines completes acquisition of EQRx; exchange ratio 0.1112

Revolution Medicines, Inc.

Acquisition closed Nov 9, 2023; EQRx stockholders received 0.1112 shares of RVMD common per EQRx share.
EQRx common stock and warrants delisted from Nasdaq; EQRx ceases as separate public company.
Sandra J. Horning appointed to RVMD board as EQRx designee, effective upon closing.
Share issuance proposal approved by ~90% of votes cast at special meeting.

item 2.01 item 5.02 item 5.07 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sandra J. Horning

Director

RVMD · Revolution Medicines, Inc.

Effective: 2023-11-09
Filed: November 9, 2023, 6:59 PM ET

the Revolution Medicines board of directors (the “Board”) appointed Sandra J. Horning, M.D., as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Sandra J. Horning was appointed as Director at Revolution Medicines, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Revolution Medicines board of directors (the “Board”) appointed Sandra J. Horning, M.D., as a member of the Board.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.98

Revolution Medicines, Inc. completed an acquisition involving EQRx, Inc. (closed 2023-11-09).

Action: acquisition
Counterparty: EQRx, Inc.
Closing: 2023-11-09

Exact text from the filing

On November 9, 2023, Revolution Medicines, Inc., a Delaware corporation (“Revolution Medicines”), completed the previously announced acquisition of EQRx, Inc., a Delaware corporation (“EQRx”)

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Revolution Medicines, Inc. shareholders approved Approval of the issuance of shares of Revolution Medicines Common Stock (including securities convertible into or exercisable for shares of Revolution Medicines Common Stock) to certain equityholders of EQRx pursuant to Merger Agreement (the "Share Issuance Proposal") at the 2023-11-08 meeting.

Proposal: merger approval
Outcome: passed
Meeting: 2023-11-08

Exact text from the filing

Proposal No. 1: Approval of the issuance of shares of Revolution Medicines Common Stock (including securities convertible into or exercisable for shares of Revolution Medicines Common Stock) to certain equityholders of EQRx pursuant to Merger Agreement (the “Share Issuance Proposal”). The Share Issuance Proposal was approved by the requisite vote of Revolution Medicines’ stockholders. Votes For Votes Against Abstentions Broker Non-Votes 85,738,003 9,442,157 123,934 —

View on SEC.gov

32 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-274137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.